Qvella Corporation

Qvella Corporation is a leader in molecular diagnostics focused on improving the speed and efficiency of diagnosing sepsis and bloodstream infections.

The company aims to transform microbiology workflows, enabling actionable information to be generated in minutes instead of days. Their mission addresses the critical need for faster diagnosis and treatment, particularly given the high mortality and treatment costs associated with sepsis. The core technology behind Qvella's innovations is FAST (Field Activated Sample Treatment), which automates and accelerates various stages of microbiology workflows. This technology allows for rapid isolation and concentration of target pathogens, producing a clean, NAAT-ready lysate in under an hour. Qvella is developing the FAST-IDTM BSI Panel to enhance the management of patients with bacteremia, providing molecular diagnostic solutions that streamline sample treatment and pathogen identification. Qvella serves hospitals, healthcare systems, and clinical laboratories in North America, focusing on those dealing with sepsis and bacteremia. Their solutions benefit all stakeholders in the healthcare ecosystem, including patients and healthcare providers, by facilitating quicker diagnostic triage and reducing treatment costs.